MetaVia Raises $8.1 Million Through Public Stock Offering for Cardiometabolic Innovation

MetaVia Raises $8.1 Million Through Public Stock Offering

On January 15, 2026, MetaVia Inc., a biotechnology firm focused on treating cardiometabolic diseases, disclosed details of a significant underwritten public offering, boasting gross proceeds of approximately $8.1 million. This funding is instrumental for the company as it continues its clinical initiatives, particularly in the development of DA-1726, a promising treatment for obesity.

The public offering consists of roughly 2,613,544 shares of common stock along with Series C and Series D Warrants each priced at $3.10 per share. Notably, the accompanying Series C Warrants and Series D Warrants are also based on the same price and are immediately exercisable. The Series C Warrants are scheduled to expire in five years, while the Series D Warrants have a shorter two-year timeline. These Warrants will be particularly relevant to investors, particularly with the potential for call options associated with positive clinical data releases in the future.

Funding Goals
MetaVia plans to allocate the proceeds from this public offering toward essential operational costs and the ongoing clinical trials for DA-1726. This candidate, an oxyntomodulin analogue, shows promising potential in managing weight loss and enhancing glucose control compared to other treatments currently available. Additionally, the innovative approach taken by DA-1726 targets both GLP-1 and glucagon receptor pathways, providing a dual mechanism that could significantly improve efficacy.

In discussing the clinical background, DA-1726 was a standout during Phase 1 trials, demonstrating excellent outcomes in weight reduction and glucose metabolism, thus marking it as a game-changer in treatment protocols for obesity—a chronic condition affecting millions worldwide. MetaVia aims to streamline the development of DA-1726 alongside other products like vanoglipel, which addresses Metabolic Dysfunction-Associated Steatohepatitis (MASH).

Potential Market Implications
The underwriters, headed by Ladenburg Thalmann & Co. Inc., hold a 45-day option to acquire additional shares and Warrants, thereby potentially increasing the total proceeds from this offering significantly. If all options are exercised, this could yield an extraordinary additional $24 million, providing further financial support for MetaVia’s ambitious plans.

MetaVia's forward-looking projections illustrate an eagerness to cater to the greater market dynamics in obesity treatment through effective capital raising and prudent deployment of resources. With the closing of this public offering anticipated on or around January 16, 2026, the company remains primed to bolster its operational framework and execute on its clinical roadmap effectively.

As investors scrutinize MetaVia's strategy and offerings, the clinical-stage company's latest financial maneuver and its dedication to treating chronic metabolic diseases underscore a commitment to advancing healthcare solutions. MetaVia's innovative trajectory could not only secure its foothold in the biotech landscape but also forge new paths in how obesity and related health issues are tackled in clinical settings.

In conclusion, the $8.1 million raised through this public stock offering plays a pivotal role in advancing MetaVia's mission. The focus remains steadfast on delivering cutting-edge solutions to address the pressing challenges of cardiometabolic diseases. This strategic funding approach serves not just as a catalyst for current projects, but also as a beacon of hope for future advancements in obesity treatment and beyond.